Myriad Genetics News

Myriad Genetics (MYGN) and GSK Unite to Boost HRD Testing

Yahoo FinanceJun 12 11:46 ET

Express News | Myriad Genetics Inc: Collaborates With GSK to Improve Access to Hrd Testing in 9 Countries

ReutersJun 11 08:12 ET

Express News | Myriad Genetics Collaborates With GSK To Improve Access On Homologous Recombination Deficiency Testing In 9 Countries

BenzingaJun 11 08:06 ET

Myriad Genetics Collaborates With GSK to Improve Access to HRD Testing in 9 Countries

SALT LAKE CITY, June 11, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced a collaboration with GSK aimed at improving access to

GlobeNewswireJun 11 08:00 ET

Myriad Genetics Insiders Sell US$5.9m Of Stock, Possibly Signalling Caution

The fact that multiple Myriad Genetics, Inc. (NASDAQ:MYGN) insiders offloaded a considerable amount of shares over the past year could have raised some eyebrows amongst investors. When evaluating in

Simply Wall StJun 5 06:09 ET

Insider Sale: Director Daniel Spiegelman Sells Shares of Myriad Genetics Inc (MYGN)

Yahoo FinanceJun 5 02:35 ET

Myriad Genetics(MYGN.US) Director Sells US$167.01K in Common Stock

$Myriad Genetics(MYGN.US)$ Director SPIEGELMAN DANIEL K sold 7,576 shares of common stock on Jun 3, 4, 2024 at an average price of $22.04 for a total value of $167.01K.Source: Announcement What is sta

moomoo NewsJun 4 18:36 ET

Express News | Myriad Genetics Launches New Universal Plus Panel For Its Foresight Carrier Screen

BenzingaJun 4 09:01 ET

Express News | Myriad Genetics Patient-Outcomes Study Validating RiskScore As Clinical Breast Cancer Risk Assessment Tool Published In Medical Genetics And Genomics

BenzingaJun 3 16:13 ET

Genetics in Medicine Publishes Myriad Genetics Patient-Outcomes Study Validating RiskScore as a Clinical Breast Cancer Risk Assessment Tool

SALT LAKE CITY, June 03, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced that Genetics in Medicine, an official journal of the American

GlobeNewswireJun 3 16:05 ET

Myriad Genetics Coverage Assumed by Jefferies at Underperform Vs Previous Rating of Hold

Myriad Genetics Coverage Assumed by Jefferies at Underperform Vs Previous Rating of Hold

Dow JonesJun 3 09:21 ET

Express News | Jefferies Assumes Myriad Genetics at Underperform, Lowers Price Target of $20

BenzingaJun 3 09:11 ET

Express News | Myriad Genetics Inc : Jefferies Assumes Coverage With Underperform Vs Hold Rating; Price Target $20 Vs $25

ReutersJun 3 02:08 ET

Qiagen, Myriad Genetics Team Up to Develop Homologous Recombination Deficiency Test

Qiagen (QGE2.VI, QIA.F) and US-based genetic testing company Myriad Genetics (MYD.F) plan to jointly develop a globally distributable kit-based test for analyzing homologous recombination deficiency s

MT NewswiresMay 31 04:19 ET

Qiagen, Myriad Genetics Partner to Create Easily Distributable Cancer Tumor Test

Qiagen (QGEN) and Myriad Genetics (MYGN) said Thursday they are working to develop a portable kit-based test for analyzing cancer patients' Homologous Recombination Deficiency status. The test will co

MT NewswiresMay 31 04:14 ET

Express News | Qiagen and Myriad Genetics Develop Distributable Homologous Recombination Deficiency Test for Global Research and Companion Diagnostics Applications

ReutersMay 30 17:56 ET

Express News | Myriad Genetics Inc:

ReutersMay 30 17:55 ET

QIAGEN And Myriad Genetics To Develop Globally Distributable Kit-Based Test For Analyzing Homologous Recombination Deficiency (HRD) Status

QIAGEN And Myriad Genetics To Develop Globally Distributable Kit-Based Test For Analyzing Homologous Recombination Deficiency (HRD) Status

BenzingaMay 30 16:30 ET

Myriad Genetics Showcases New Research and Product Innovations Advancing Cancer Care at 2024 ASCO Annual Meeting

SALT LAKE CITY, May 23, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, and its collaborators will share data from seven studies at the 2024 ASCO

GlobeNewswireMay 23 18:00 ET

New Study Published in JCO Precision Oncology Shows Myriad Genetics' Prolaris Test Can Predict Benefit of Hormone Therapy Treatment in Men With Localized Prostate Cancer

Myriad's Prolaris Test is the only biomarker test to quantify the benefits of adding androgen deprivation therapy to radiation therapy1 SALT LAKE CITY, May 16, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc.

GlobeNewswireMay 16 16:05 ET